Read our latest updates & insights

On 13 May 2024, Novo Holdings A/S announced the acquisition of a 60% majority stake in growing Austrian life sciences tools company Single Use Support.   The two co-founders of Single Use Support will each retain a 10% stake, and Danaher Corporation will hold the remaining ...

On 13 May 2024, Novo Nordisk announced positive results from the FRONTIER 2 trial, a 26-week phase 3a study evaluating the efficacy and safety of once-weekly and once-monthly subcutaneous administration of Mim8 for the treatment for haemophilia A.  The study demonstrated th...

On 6 May 2024, by order unsealed on 10 May 2024, the United States District Court for the District of Delaware refused to grant Alexion injunctive relief against Samsung Bioepis for alleged infringement of claims of two Alexion patents relating to methods for treating parox...

On 10 May 2024, Xbrane and Stada announced the exclusive licensing agreement with US biosimilars specialist Valorum Biologics for their ranibizumab biosimilar candidate.
Swedish biosimilar developer Xbrane and Germany’s STADA are responsible for completing the regulat...

On 9 May 2024, Rani Therapeutics announced that it will present pre-clinical and clinical data at Digestive Disease Week in the US (18-21 May 2024) regarding RT-111, an oral delivery platform known as the RaniPill® capsule, containing Celltrion’s ustekinumab biosimilar, CT-...

On 8 May 2024, Telix announced an agreement with Cardinal Health Nuclear & Precision Health Solutions for the global clinical supply of actinium-225 (Ac-225). This therapeutic radioisotope will support the development of Telix’s targeted alpha therapy (TAT) pipeli...

On 7 May 2024, Galderma announced that its nemolizumab, for the treatment of prurigo nodularis and for moderate to severe atopic dermatitis has been accepted for review in Australia, Singapore, Switzerland and the UK under the Access Consortium Framework, a collaboration be...

On 7 May 2024, the EU Medicines Agency (EMA) withdrew marketing authorisation (MA) approval for AZ’s COVID-19 vaccine Vaxzevria, at AZ’s request. AZ requested   the withdrawal reportedly due to decline in demand for the vaccine and it no longer being manufactured or s...

On 7 May 2024, Pharma In Focus reported that Arrotex has partnered with Amgen to promote Amgen’s Prolia® (denosumab) in Australia.  It is planned that the partnership “will support the future growth of Prolia in the Australian market, utilising the infrastructure and reach ...